[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2018120104A1 - System and method for closed loop control in artificial pancreas - Google Patents

System and method for closed loop control in artificial pancreas Download PDF

Info

Publication number
WO2018120104A1
WO2018120104A1 PCT/CN2016/113690 CN2016113690W WO2018120104A1 WO 2018120104 A1 WO2018120104 A1 WO 2018120104A1 CN 2016113690 W CN2016113690 W CN 2016113690W WO 2018120104 A1 WO2018120104 A1 WO 2018120104A1
Authority
WO
WIPO (PCT)
Prior art keywords
artificial pancreas
patient
processer
closed loop
algorithms
Prior art date
Application number
PCT/CN2016/113690
Other languages
French (fr)
Inventor
Cuijun YANG
Original Assignee
Medtrum Technologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtrum Technologies Inc. filed Critical Medtrum Technologies Inc.
Priority to US16/471,569 priority Critical patent/US11534548B2/en
Priority to EP16925387.9A priority patent/EP3562395A4/en
Priority to PCT/CN2016/113690 priority patent/WO2018120104A1/en
Publication of WO2018120104A1 publication Critical patent/WO2018120104A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
    • A61B5/1118—Determining activity level
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/683—Means for maintaining contact with the body
    • A61B5/6832—Means for maintaining contact with the body using adhesives
    • A61B5/6833—Adhesive patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/02—Operational features
    • A61B2560/0204—Operational features of power management
    • A61B2560/0214—Operational features of power management of power generation or supply
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/04—Constructional details of apparatus
    • A61B2560/0462—Apparatus with built-in sensors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
    • A61B5/0024—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system for multiple sensor units attached to the patient, e.g. using a body or personal area network
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • A61M2005/1726—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure the body parameters being measured at, or proximate to, the infusion site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/18—General characteristics of the apparatus with alarm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3303—Using a biosensor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3546—Range
    • A61M2205/3569—Range sublocal, e.g. between console and disposable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/201—Glucose concentration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/63—Motion, e.g. physical activity

Definitions

  • This invention generally relates to medical appliance, and more specifically to a system and method for adjustment of blood glucose related algorithm in a close loop artificial pancreas.
  • the pancreas produces and releases insulin into the blood stream in response to elevated blood glucose levels.
  • ⁇ -cells which reside in the pancreas, produce and secrete the insulin into the blood stream, as it is needed. If ⁇ -cells become incapacitated or die, a condition known as Type I diabetes mellitus, or in some cases if ⁇ -cells produce insufficient quantities of insulin, Type II diabetes, then insulin must be provided to the body of the patient from another source.
  • infusion pump therapy has been increasing, especially for delivering insulin for diabetics.
  • external infusion pumps are worn on a belt, in a pocket, or patched to the body of the patient directly, and deliver insulin into the body via an infusion tube with a percutaneous needle or a cannula placed in the subcutaneous tissue.
  • the medicine that is delivered by the infusion pump device can depend on the condition of the patient and the desired treatment plan.
  • current insulin pumps and other diabetes treatment instruments are limited in switching between different treatment plans based on different conditions of the patient.
  • Desired treatment plans using a closed loop algorithm depend on accurate determination of the physical conditions of the patient, especially for the continuously glucose monitoring in tissue fluid whose concentration is easily influenced by the actions of the patient. If a patient is in sleep, due to less activity taking place in the muscle and organs than the normal state, whether she or he needs a low suspend or predictive low suspend requires to be recalculated by adjusted algorithms. Furthermore, some low-priority alerts should be muted to prevent disturbing the patient from sleep. Similarly, if a patient is doing physical exercise, her or his interstitial glucose value sensed by the glucose sensor may fluctuate sharply because of the frequent changes in the tissue fluid, but her or his glucose level should not be determined as abnormal. To realize the closed loop algorithm in an artificial pancreas, the combination of sensing the activity level of the patient and adjusting related algorithms is crucial.
  • one purpose of the present invention is to provide a method to realize a closed loop control in an artificial pancreas, comprising,
  • the motion sensor comprises one or more from an accelerometer, a gyroscope and an attitude sensor.
  • the method further comprises adjusting the algorithms according to different exercise intensities when the patient is in a physical exercise state.
  • the blood glucose related algorithms comprise a low-suspend algorithm, a predictive low-suspend algorithm, and an alert threshold algorithm.
  • the method further comprises automatically switching the closed loop artificial pancreas between different operation modes based at least partly on the adjusted algorithms.
  • the method further comprises automatically adjusting the insulin delivery of a basal rate mode of the closed loop artificial pancreas based at least partly on the adjusted algorithms.
  • the method further comprises automatically switching the closed loop artificial pancreas to an audio-off mode for low-priority alerts that do not require immediate action according to the adjusted algorithms.
  • the other purpose of the present invention is to provide a closed loop artificial pancreas using the method identified above, comprising,
  • CGM continuous glucose monitoring
  • At least one processer set in any component of artificial pancreas configured to determine the physical states of the patient, adjust related algorithms and send corresponding instructions based partly on the signals.
  • the closed loop artificial pancreas further comprises a handset
  • At least one motion sensor is set in the patch pump, the CGM system or the handset, configured to sense the activity levels of a patient and provide corresponding signals;
  • At least one processer is set in the patch pump, the CGM system or the handset, configured to determine the physical states of the patient, adjust related algorithms and send corresponding instructions based partly on the signals.
  • the patch pump and the CGM system are separated from each other; at least one motion sensor is set in the patch pump or the CGM system, and two processers are set in the patch pump and the CGM system respectively.
  • the patch pump and the CGM system are integrated in a single-needle-integrated artificial pancreas in which both a motion sensor and a processer are set.
  • the present invention has advantages in the following ways: Firstly, applying the motion sensors in the close loop artificial pancreas enables a comprehensive grasp of the patient's activity levels for a more rational treatment by distinguishing sleep and physical exercise states from the normal state; secondly, adjusting blood glucose related algorithms according to different activity levels and exercise intensities of the patient provides more applicable data and enables automatic operations of the artificial pancreas, such as suspending the delivery under low glucose condition, switching between different operation modes and adjusting insulin delivery of specific operation mode, which reflect the advantages of the closed loop control of artificial pancreas in an all-round way; thirdly, muting some low-priority alerts when sensing the patient in the state of sleep or physical exercise can reduce unnecessary disturbance to the patient making the system more pleasant to use.
  • the application of motion sensors in the close loop artificial pancreas enables algorithm adjustments based on different physical states and exercise intensities of the patient to provide more accurate and reliable blood glucose related data that is the basis of desirable treatment plans, and a closed loop artificial pancreas using this method satisfies the requirements of the patient on safety and intelligence of a diabetes treatment system in a more sophisticated way.
  • FIG. 1-3 are schematic diagrams of a patient wearing an artificial pancreas in the present invention
  • FIG. 4-9 are schematic diagrams of representative method in the embodiments of the present invention.
  • FIG. 1 illustrates a patient wearing a CGM system 1 configured to monitor the blood glucose changes in real time and a patch pump 2 configured to deliver insulin to the patient, both equipped with a processor, which communicates with each other via a processor set in a portable handset 3 configured to receive signals, process and display data, and send instructions.
  • At least one motion sensor is set in any one, or two, or all three of the CGM system 1, the patch pump 2 and the handset 3, which will be described in following paragraphs.
  • FIG. 2 illustrates a patient wearing an artificial pancreas comprising two separate components: a CGM system 1 and a patch pump 2, which communicate with each other via their respective processers. At least one motion sensor is set in the CGM system 1 and/or the patch pump 2, which will be described in following paragraphs.
  • FIG. 3 illustrates a patient wearing a single-needle-integrated artificial pancreas integrated by a patch pump 2 and a built-in CGM system 1.
  • a processer is set in the single-needle-integrated artificial pancreas to perform all the functions including receiving signals, processing data, and sending instructions.
  • a motion sensor is also set in the single-needle-integrated artificial pancreas.
  • a motion sensor 101 is set in the CGM system 1, configured to sense activity levels of the patient and send corresponding signals.
  • a processer 102 in the CGM system 1 receives signals from the motion sensor 101 and adjusts related algorithms depending partly on the signals, and the data processed using the adjusted algorithms is sent to a processer 302 in a handset 3.
  • the processer 302 determines whether an operation of the patch pump 2 is needed. If so, the processer 302 sends an instruction to the processer 202 of the patch pump 2 to perform the corresponding operation automatically.
  • the motion sensor 101 is a three-axis accelerometer 101.
  • ACC power is the acceleration amplitude of all three axes
  • ACC X is the acceleration data of the X axis
  • ACC Y is the acceleration data of the Y axis
  • ACC Z is the acceleration data of the Z axis.
  • the attitudes of the patient can be sensed by the three-axis accelerometer 101.
  • the attitude changes of the patient can be tracked by the three-axis accelerometer 101 in real time.
  • the state can be determined by the equation:
  • ACC var (ACC X -ACC X
  • ACC var is the acceleration variation of all three axes
  • ACC X is the acceleration data of the X axis
  • ACC Y is the acceleration data of the Y axis
  • ACC Z is the acceleration data of the Z axis
  • PRE is the acceleration data of the X axis at a previous time
  • PRE is the acceleration data of the Y axis at a previous time
  • PRE is the acceleration data of the Z axis at a previous time.
  • the algorithms adjusted by the processer 102 comprise but not limited to a low-suspend algorithm, a predictive low-suspend algorithm; and an alert threshold algorithm. As shown in FIG. 4, data processed according to the adjusted algorithms is sent to the handset 3, and the processer 302 in the handset 3 determines whether an operation should be performed automatically by the patch pump 2. If so, the processer 302 sends an instruction to the processer 202 of the patch pump 2.
  • the operations comprise but not limited to a delivery suspend according to the low-suspend algorithm or the predictive low-suspend algorithm, a change of operation modes, an adjustment of the insulin delivery amount of a basal rate mode, and switching the CGM system 1 and the patch pump 2 into an audio-off mode for low priority alerts according to the adjusted algorithm when the patient is determined in a state of sleep or physical exercise.
  • a motion sensor 101 is set in the CGM system 1, and the signals provided by the motion sensor 101 are sent to and processed by a processer 302 set in the handset 3 via a transmitting module 1021 set in the CGM system 1.
  • the processer 302 in the handset 3 adjusts related algorithms depending partly on the signals, and determines whether an operation of the patch pump 2 is needed. If so, the processer 302 sends an instruction to the processer 202 of the patch pump 2 to perform the corresponding operation automatically.
  • a motion sensor 301 is set in a portable handset 3 to sense the activity levels of the patient when the patient is carrying the handset 3, and the signals provided by the motion sensor 301 are sent to and processed by a processer 302 set in the handset 3.
  • the processer 302 in the handset 3 adjusts related algorithms depending partly on the signals, and processes the glucose data provided by a processer 102 of the CGM system 1 accordingly.
  • the processer 302 in the handset 3 further determines whether an operation of the patch pump 2 is needed. If so, the processer 302 of the handset 3 sends an instruction to the processer 202 of the patch pump 2 to perform the corresponding operation automatically.
  • a motion sensor 101 is set in the CGM system 1, and the signals provided by the motion sensor 101 are sent to and processed by a processer 102 which is also set in the CGM system 1.
  • the processer 102 adjusts related algorithms depending partly on the signals, and the data processed using the adjusted algorithm is sent to a processer 202 in a patch pump 2 directly.
  • the processer 202 determines whether an operation of the patch pump 2 is needed. If so, an instruction is generated from the processer 202 for the patch pump 2 to perform the corresponding operation automatically.
  • a motion sensor 201 is set in the patch pump 2, and the signals provided by the motion sensor 201 are sent to the processer 202 which is also set in the patch pump 2.
  • the processer 202 determines the physical state of the patient, in specific, whether the patient is in sleep or doing physical exercise, then switches the patch pump 2 to an appropriate operation mode according to the state of the patient automatically.
  • the processer 202 sends a signal comprising the physical state and exercise intensity of the patient to the processer 102 of the CGM system to adjust related algorithms, calculating the blood glucose values based on the adjusted algorithms which reflect the actual state of the patient.
  • a single-needle-integrated artificial pancreas comprises a patch pump 2 and a built-in glucose sensor 111 in FIG. 9.
  • a motion sensor 201 is set in the single-needle-integrated artificial pancreas, and a processer 202 configured to perform all the functions of receiving signals, processing data, and sending instructions is also set in the single-needle-integrated artificial pancreas.
  • the motion sensor 201 senses activity levels of the patient and send corresponding signals to the processer 202.
  • the processer 202 receives signals from the motion sensor 201 and adjusts related algorithms depending partly on the signals to process the glucose data received from the built-in glucose sensor 111, and determines whether an operation of the single-needle-integrated artificial pancreas is needed. If so, an instruction is generated from the processer 202 for the patch pump 2 to perform the corresponding operation automatically, realizing the closed loop control in the single-needle-integrated artificial pancreas.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Emergency Medicine (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Business, Economics & Management (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Business, Economics & Management (AREA)
  • External Artificial Organs (AREA)

Abstract

Closed loop control method in artificial pancreas and system using the same, the method comprising: sensing an activity level of a patient by at least one motion sensor (101, 201, 301) and providing signals to at least one processer (102, 202, 302); then adjusting a series of related algorithms depending partly on the signals by the processer (102, 202, 302) to provide more accurate and reliable data that is the basis of desirable treatment plans, and sending corresponding instructions by the processer (102, 202, 302) for automatic operations of the artificial pancreas to realize a closed loop control.

Description

SYSTEM AND METHOD FOR A CLOSED LOOP CONTROL IN AN ARTIFICIAL PANCREAS TECHNICAL FIELD
This invention generally relates to medical appliance, and more specifically to a system and method for adjustment of blood glucose related algorithm in a close loop artificial pancreas.
BACKGROUND
For a normal healthy person, the pancreas produces and releases insulin into the blood stream in response to elevated blood glucose levels. β-cells, which reside in the pancreas, produce and secrete the insulin into the blood stream, as it is needed. If β-cells become incapacitated or die, a condition known as Type I diabetes mellitus, or in some cases if β-cells produce insufficient quantities of insulin, Type II diabetes, then insulin must be provided to the body of the patient from another source.
Traditionally, since insulin cannot be taken orally, insulin has been injected with a syringe. More recently, use of infusion pump therapy has been increasing, especially for delivering insulin for diabetics. For example, external infusion pumps are worn on a belt, in a pocket, or patched to the body of the patient directly, and deliver insulin into the body via an infusion tube with a percutaneous needle or a cannula placed in the subcutaneous tissue. The medicine that is delivered by the infusion pump device can depend on the condition of the patient and the desired treatment plan. However, current insulin pumps and other diabetes treatment instruments are limited in switching between different treatment plans based on different conditions of the patient.
Desired treatment plans using a closed loop algorithm depend on accurate determination of the physical conditions of the patient, especially for the continuously glucose monitoring in tissue fluid whose concentration is easily influenced by the actions of the patient. If a patient is in sleep, due to less activity taking place in the muscle and organs than the normal state, whether she or he needs a low suspend or predictive low suspend requires to be recalculated by adjusted algorithms. Furthermore, some low-priority alerts should be muted to prevent disturbing the patient from sleep. Similarly, if a patient is doing physical exercise, her or his interstitial glucose value sensed by the glucose sensor may fluctuate sharply because of the frequent changes in the tissue fluid, but her or his glucose level should not be determined as abnormal. To realize the closed loop algorithm in an artificial pancreas, the combination of sensing the activity level of the patient and adjusting related algorithms is crucial.
SUMMARY OF THE INVENTION
To overcome the deficiencies of the prior art, one purpose of the present invention is to provide a method to realize a closed loop control in an artificial pancreas, comprising,
sensing an activity level of a patient and providing signals indicative of the activity level by at least one motion sensor to at least one processer；
determining the physical state of the patient according to the activity level and adjusting a plurality of algorithms via the processer depending partly on the signals from the motion sensor, and sending corresponding instructions via the processer based on the adjusted algorithms for automatic operations to realize the closed loop control.
Alternatively, the motion sensor comprises one or more from an accelerometer, a gyroscope and an attitude sensor.
Alternatively, the method further comprises adjusting the algorithms according to different exercise intensities when the patient is in a physical exercise state.
Alternatively, the blood glucose related algorithms comprise a low-suspend algorithm, a predictive low-suspend algorithm, and an alert threshold algorithm.
Alternatively, the method further comprises automatically switching the closed loop artificial pancreas between different operation modes based at least partly on the adjusted algorithms.
Alternatively, the method further comprises automatically adjusting the insulin delivery of a basal rate mode of the closed loop artificial pancreas based at least partly on the adjusted algorithms.
Alternatively, the method further comprises automatically switching the closed loop artificial pancreas to an audio-off mode for low-priority alerts that do not require immediate action according to the adjusted algorithms.
The other purpose of the present invention is to provide a closed loop artificial pancreas using the method identified above, comprising,
a patch pump and a continuous glucose monitoring (CGM) system；
at least one motion sensor set in any component of artificial pancreas, configured to sense the activity levels of a patient and provide corresponding signals；
at least one processer set in any component of artificial pancreas, configured to determine the physical states of the patient, adjust related algorithms and send corresponding instructions based partly on the signals.
Alternatively, the closed loop artificial pancreas further comprises a handset；
at least one motion sensor is set in the patch pump, the CGM system or the handset, configured to sense the activity levels of a patient and provide corresponding signals；
at least one processer is set in the patch pump, the CGM system or the handset, configured to determine the physical states of the patient, adjust related algorithms and send corresponding instructions based partly on the signals.
Alternatively, the patch pump and the CGM system are separated from each other； at least one motion sensor is set in the patch pump or the CGM system, and two processers are set in the patch pump and the CGM system respectively.
Alternatively, the patch pump and the CGM system are integrated in a single-needle-integrated artificial pancreas in which both a motion sensor and a processer are set.
The present invention has advantages in the following ways: Firstly, applying the motion sensors in the close loop artificial pancreas enables a comprehensive grasp of the patient's activity levels for a more rational treatment by distinguishing sleep and physical exercise states from the normal state； secondly, adjusting blood glucose related algorithms according to different activity levels and exercise intensities of the patient provides more applicable data and enables automatic operations of the artificial pancreas, such as suspending the delivery under low glucose condition, switching between different operation modes and adjusting insulin delivery of specific operation mode, which reflect the advantages of the closed loop control of artificial pancreas in an all-round way； thirdly, muting some low-priority alerts when sensing the patient in the state of sleep or physical exercise can reduce unnecessary disturbance to the patient making the system more pleasant to use. To sum up, the application of motion sensors in the close loop artificial pancreas enables algorithm adjustments based on different physical states and exercise intensities of the patient to provide more accurate and reliable blood glucose related data that is the basis of desirable treatment plans, and a closed loop artificial pancreas using this method satisfies the requirements of the patient on safety and intelligence of a diabetes treatment system in a more sophisticated way.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1-3 are schematic diagrams of a patient wearing an artificial pancreas in the present invention 
FIG. 4-9 are schematic diagrams of representative method in the embodiments of the present invention 
DETAILED DESCRIPTION
To make the above-mentioned objects, features and advantages of the present invention more obvious and understandable, the embodiments of the present invention are described in the following through specific embodiments.
Referring to FIG. 1, an embodiment of the system using the closed loop control in the present invention is provided. FIG. 1 illustrates a patient wearing a CGM system 1 configured to monitor the blood glucose changes in real time and a patch pump 2 configured to deliver insulin  to the patient, both equipped with a processor, which communicates with each other via a processor set in a portable handset 3 configured to receive signals, process and display data, and send instructions. At least one motion sensor is set in any one, or two, or all three of the CGM system 1, the patch pump 2 and the handset 3, which will be described in following paragraphs.
Referring to FIG. 2, an embodiment of the system using the closed loop control in the present invention is provided. FIG. 2 illustrates a patient wearing an artificial pancreas comprising two separate components: a CGM system 1 and a patch pump 2, which communicate with each other via their respective processers. At least one motion sensor is set in the CGM system 1 and/or the patch pump 2, which will be described in following paragraphs.
Referring to FIG. 3, an embodiment of the system using the closed loop control in the present invention is provided. FIG. 3 illustrates a patient wearing a single-needle-integrated artificial pancreas integrated by a patch pump 2 and a built-in CGM system 1. A processer is set in the single-needle-integrated artificial pancreas to perform all the functions including receiving signals, processing data, and sending instructions. A motion sensor is also set in the single-needle-integrated artificial pancreas.
Referring to FIG. 1 and FIG. 4, an embodiment of the present invention is provided. As shown in FIG. 4, a motion sensor 101 is set in the CGM system 1, configured to sense activity levels of the patient and send corresponding signals. A processer 102 in the CGM system 1 receives signals from the motion sensor 101 and adjusts related algorithms depending partly on the signals, and the data processed using the adjusted algorithms is sent to a processer 302 in a handset 3. Through further processing, the processer 302 determines whether an operation of the patch pump 2 is needed. If so, the processer 302 sends an instruction to the processer 202 of the patch pump 2 to perform the corresponding operation automatically.
In this embodiment, the motion sensor 101 is a three-axis accelerometer 101.
When the patient is in physical exercise, the start and end of the exercise, as well as the intensity of the exercise can be determined by the equation:
Figure PCTCN2016113690-appb-000001
Where,
ACCpower is the acceleration amplitude of all three axes；
ACCX is the acceleration data of the X axis；
ACCY is the acceleration data of the Y axis；
ACCZ is the acceleration data of the Z axis.
The attitudes of the patient, whether she or he is standing, sitting, lying, or changing from one of these attitudes to another, can be sensed by the three-axis accelerometer 101. In other  words, the attitude changes of the patient can be tracked by the three-axis accelerometer 101 in real time. When the patient goes to sleep, the state can be determined by the equation:
ACCvar ＝ (ACCX-ACCX|PRE) 2+ (ACCY-ACCY|PRE) 2+ (ACCZ-ACCZ|PRE) 2
Where,
ACCvar is the acceleration variation of all three axes；
ACCX is the acceleration data of the X axis；
ACCY is the acceleration data of the Y axis；
ACCZ is the acceleration data of the Z axis；
ACCX|PRE is the acceleration data of the X axis at a previous time；
ACCY|PRE is the acceleration data of the Y axis at a previous time；
ACCZ|PRE is the acceleration data of the Z axis at a previous time.
The algorithms adjusted by the processer 102 comprise but not limited to a low-suspend algorithm, a predictive low-suspend algorithm； and an alert threshold algorithm. As shown in FIG. 4, data processed according to the adjusted algorithms is sent to the handset 3, and the processer 302 in the handset 3 determines whether an operation should be performed automatically by the patch pump 2. If so, the processer 302 sends an instruction to the processer 202 of the patch pump 2. The operations comprise but not limited to a delivery suspend according to the low-suspend algorithm or the predictive low-suspend algorithm, a change of operation modes, an adjustment of the insulin delivery amount of a basal rate mode, and switching the CGM system 1 and the patch pump 2 into an audio-off mode for low priority alerts according to the adjusted algorithm when the patient is determined in a state of sleep or physical exercise.
Referring to FIG. 1 and FIG. 5, an embodiment of the present invention is provided. As shown in FIG. 5, a motion sensor 101 is set in the CGM system 1, and the signals provided by the motion sensor 101 are sent to and processed by a processer 302 set in the handset 3 via a transmitting module 1021 set in the CGM system 1. The processer 302 in the handset 3 adjusts related algorithms depending partly on the signals, and determines whether an operation of the patch pump 2 is needed. If so, the processer 302 sends an instruction to the processer 202 of the patch pump 2 to perform the corresponding operation automatically.
Referring to FIG. 1 and FIG. 6, an embodiment of the present invention is provided. As shown in FIG. 6, a motion sensor 301 is set in a portable handset 3 to sense the activity levels of the patient when the patient is carrying the handset 3, and the signals provided by the motion sensor 301 are sent to and processed by a processer 302 set in the handset 3. The processer 302 in the handset 3 adjusts related algorithms depending partly on the signals, and processes the glucose  data provided by a processer 102 of the CGM system 1 accordingly. The processer 302 in the handset 3 further determines whether an operation of the patch pump 2 is needed. If so, the processer 302 of the handset 3 sends an instruction to the processer 202 of the patch pump 2 to perform the corresponding operation automatically.
Referring to FIG. 2 and FIG. 7, an embodiment of the present invention is provided. As shown in FIG. 7, a motion sensor 101 is set in the CGM system 1, and the signals provided by the motion sensor 101 are sent to and processed by a processer 102 which is also set in the CGM system 1. The processer 102 adjusts related algorithms depending partly on the signals, and the data processed using the adjusted algorithm is sent to a processer 202 in a patch pump 2 directly. Through further processing, the processer 202 determines whether an operation of the patch pump 2 is needed. If so, an instruction is generated from the processer 202 for the patch pump 2 to perform the corresponding operation automatically.
Referring to FIG. 2 and FIG. 8, an embodiment of the present invention is provided. As shown in FIG. 8, a motion sensor 201 is set in the patch pump 2, and the signals provided by the motion sensor 201 are sent to the processer 202 which is also set in the patch pump 2. The processer 202 determines the physical state of the patient, in specific, whether the patient is in sleep or doing physical exercise, then switches the patch pump 2 to an appropriate operation mode according to the state of the patient automatically. At the same time, the processer 202 sends a signal comprising the physical state and exercise intensity of the patient to the processer 102 of the CGM system to adjust related algorithms, calculating the blood glucose values based on the adjusted algorithms which reflect the actual state of the patient.
Referring to FIG. 3 and FIG. 9, an embodiment of the present invention is provided. As shown in FIG. 9, a single-needle-integrated artificial pancreas comprises a patch pump 2 and a built-in glucose sensor 111 in FIG. 9. A motion sensor 201 is set in the single-needle-integrated artificial pancreas, and a processer 202 configured to perform all the functions of receiving signals, processing data, and sending instructions is also set in the single-needle-integrated artificial pancreas. The motion sensor 201 senses activity levels of the patient and send corresponding signals to the processer 202. The processer 202 receives signals from the motion sensor 201 and adjusts related algorithms depending partly on the signals to process the glucose data received from the built-in glucose sensor 111, and determines whether an operation of the single-needle-integrated artificial pancreas is needed. If so, an instruction is generated from the processer 202 for the patch pump 2 to perform the corresponding operation automatically, realizing the closed loop control in the single-needle-integrated artificial pancreas.
The above descriptions of the detailed embodiments are only to illustrate the principle and  the effect of the present invention, and it is not to limit the scope of the present invention. Those skilled in the art can modify or change the embodiments without departing from the spirit and scope of the present invention. Accordingly, all equivalent modifications and variations completed by persons of ordinary skill in the art, without departing from the spirit and technical idea of the present invention, should fall within the scope of the present disclosure defined by the appended claims.

Claims (12)

  1. A method to realize a closed loop control in an artificial pancreas, comprising:
    sensing an activity level of a patient by at least one motion sensor set in an artificial pancreas；
    providing signals indicative of the activity level of the patient by the motion sensor to at least one processer of the artificial pancreas；
    determining the physical state of the patient according to the activity level via the processer；
    adjusting a plurality of algorithms via the processer depending partly on the signals from the motion sensor；
    sending corresponding instructions based on the adjusted algorithms via the processer for automatic operations of the artificial pancreas.
  2. The method according to Claim 1, wherein,
    the motion sensor comprises one or more from an accelerometer, a gyroscope and an attitude sensor.
    The method according to Claim 1, wherein,
    further comprises adjusting the algorithms according to different exercise intensities when the patient is in a physical exercise state.
  3. The method according to Claim 1, wherein,
    the algorithms comprise a low‐suspend algorithm.
  4. The method according to Claim 1, wherein,
    the algorithms comprise a predicted low‐suspend algorithm.
  5. The method according to Claim 1, wherein,
    the algorithms comprise an alert threshold algorithm.
  6. The method according to Claim 1, wherein,
    further comprises automatically switching the closed loop artificial pancreas between different operation modes based at least partly on the adjusted algorithms.
  7. The method according to Claim 1, wherein,
    further comprises automatically adjusting the insulin delivery of a basal rate mode of the closed loop artificial pancreas based at least partly on the adjusted algorithms.
  8. The method according to Claim 1, wherein,
    further comprises automatically switching the closed loop artificial pancreas to an audio‐off mode for low‐priority alerts that do not require immediate action according to the adjusted algorithms.
  9. A closed loop artificial pancreas using the method according to Claim 1, comprising,
    a patch pump and a continuous glucose monitoring (CGM) system；
    at least one motion sensor set in any component of artificial pancreas, configured to sense the activity levels of a patient and provide corresponding signals；
    at least one processer set in any component of artificial pancreas, configured to determine the physical states of the patient, adjust related algorithms and send corresponding instructions based partly on the signals.
  10. A closed loop artificial pancreas according to Claim 10, wherein,
    further comprises a handset；
    at least one motion sensor is set in the patch pump, the CGM system or the handset, configured to sense the activity levels of a patient and provide corresponding signals；
    at least one processer is set in the patch pump, the CGM system or the handset, configured to determine the physical states of the patient, adjust related algorithms and send corresponding instructions based partly on the signals.
  11. A closed loop artificial pancreas according to Claim 10, wherein,
    the patch pump and the CGM system are separated from each other；
    at least one motion sensor is set in the patch pump or the CGM system；
    two processers are set in the patch pump and the CGM system respectively.
  12. A closed loop artificial pancreas according to Claim 10, wherein,
    the patch pump and the CGM system are integrated in a single‐needle‐integrated artificial pancreas；
    both a motion sensor and a processer are set in the single‐needle‐integrated artificial pancreas.
PCT/CN2016/113690 2016-12-30 2016-12-30 System and method for closed loop control in artificial pancreas WO2018120104A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/471,569 US11534548B2 (en) 2016-12-30 2016-12-30 System and method for a closed loop control in an artificial pancreas
EP16925387.9A EP3562395A4 (en) 2016-12-30 2016-12-30 System and method for closed loop control in artificial pancreas
PCT/CN2016/113690 WO2018120104A1 (en) 2016-12-30 2016-12-30 System and method for closed loop control in artificial pancreas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/113690 WO2018120104A1 (en) 2016-12-30 2016-12-30 System and method for closed loop control in artificial pancreas

Publications (1)

Publication Number Publication Date
WO2018120104A1 true WO2018120104A1 (en) 2018-07-05

Family

ID=62706706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/113690 WO2018120104A1 (en) 2016-12-30 2016-12-30 System and method for closed loop control in artificial pancreas

Country Status (3)

Country Link
US (1) US11534548B2 (en)
EP (1) EP3562395A4 (en)
WO (1) WO2018120104A1 (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020069406A1 (en) * 2018-09-28 2020-04-02 Insulet Corporation Activity mode for artificial pancreas system
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
WO2022116539A1 (en) * 2020-01-21 2022-06-09 Medtrum Technologies Inc. Analyte detection system
US11386996B2 (en) 2014-01-30 2022-07-12 Insulet Netherlands B.V. Therapeutic product delivery system and method of pairing
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11565043B2 (en) 2018-05-04 2023-01-31 Insulet Corporation Safety constraints for a control algorithm based drug delivery system
US11565039B2 (en) 2018-10-11 2023-01-31 Insulet Corporation Event detection for drug delivery system
US11596740B2 (en) 2015-02-18 2023-03-07 Insulet Corporation Fluid delivery and infusion devices, and methods of use thereof
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US11724027B2 (en) 2016-09-23 2023-08-15 Insulet Corporation Fluid delivery device with sensor
US11738144B2 (en) 2021-09-27 2023-08-29 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
US11857763B2 (en) 2016-01-14 2024-01-02 Insulet Corporation Adjusting insulin delivery rates
US11865299B2 (en) 2008-08-20 2024-01-09 Insulet Corporation Infusion pump systems and methods
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
US11929158B2 (en) 2016-01-13 2024-03-12 Insulet Corporation User interface for diabetes management system
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
USD1020794S1 (en) 2018-04-02 2024-04-02 Bigfoot Biomedical, Inc. Medication delivery device with icons
US11957875B2 (en) 2019-12-06 2024-04-16 Insulet Corporation Techniques and devices providing adaptivity and personalization in diabetes treatment
USD1024090S1 (en) 2019-01-09 2024-04-23 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery
US11969579B2 (en) 2017-01-13 2024-04-30 Insulet Corporation Insulin delivery methods, systems and devices
US11986630B2 (en) 2020-02-12 2024-05-21 Insulet Corporation Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk
EP4149584A4 (en) * 2019-05-17 2024-06-05 Medtrum Technologies Inc. Bilaterally driven closed-loop artificial pancreas
US12036389B2 (en) 2020-01-06 2024-07-16 Insulet Corporation Prediction of meal and/or exercise events based on persistent residuals
US12042630B2 (en) 2017-01-13 2024-07-23 Insulet Corporation System and method for adjusting insulin delivery
US12064591B2 (en) 2013-07-19 2024-08-20 Insulet Corporation Infusion pump system and method
US12076160B2 (en) 2016-12-12 2024-09-03 Insulet Corporation Alarms and alerts for medication delivery devices and systems
US12097355B2 (en) 2023-01-06 2024-09-24 Insulet Corporation Automatically or manually initiated meal bolus delivery with subsequent automatic safety constraint relaxation
US12106837B2 (en) 2016-01-14 2024-10-01 Insulet Corporation Occlusion resolution in medication delivery devices, systems, and methods
US12115351B2 (en) 2020-09-30 2024-10-15 Insulet Corporation Secure wireless communications between a glucose monitor and other devices
US12121701B2 (en) 2021-01-29 2024-10-22 Insulet Corporation Systems and methods for incorporating co-formulations of insulin in an automatic insulin delivery system
US12121700B2 (en) 2020-07-22 2024-10-22 Insulet Corporation Open-loop insulin delivery basal parameters based on insulin delivery records
US12128215B2 (en) 2020-09-30 2024-10-29 Insulet Corporation Drug delivery device with integrated optical-based glucose monitor

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952361T3 (en) 2009-08-31 2023-10-31 Abbott Diabetes Care Inc Displays for a medical device
US9872641B2 (en) 2012-11-29 2018-01-23 Abbott Diabetes Care Inc. Methods, devices, and systems related to analyte monitoring
EP3562380A4 (en) * 2016-12-30 2020-08-12 Medtrum Technologies Inc. System and method for algorithm adjustment applying motion sensors in cgm system
US11992656B2 (en) * 2019-08-29 2024-05-28 Medtronic Minimed, Inc. Controlling medical infusion device operation and features based on detected patient sleeping status
US11938301B2 (en) 2019-12-13 2024-03-26 Medtronic Minimed, Inc. Controlling medication delivery system operation and features based on automatically detected muscular movements
US11887712B2 (en) 2019-12-13 2024-01-30 Medtronic Minimed, Inc. Method and system for classifying detected events as labeled event combinations for processing at a client application
USD948723S1 (en) * 2020-08-27 2022-04-12 Medtrum Technologies Inc. Installer for body fluid analyte detection device
US11311666B1 (en) 2021-02-18 2022-04-26 Fresenius Kabi Deutschland Gmbh Modular wearable medicament delivery device and method of use thereof
US11464902B1 (en) 2021-02-18 2022-10-11 Fresenius Kabi Deutschland Gmbh Wearable medicament delivery device with compressible reservoir and method of use thereof
WO2023212000A1 (en) * 2022-04-27 2023-11-02 The Trustees Of The University Ofpennsylvania Wearable device for recognition and response to an overdose

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070255122A1 (en) * 2004-08-30 2007-11-01 G.R. Enlightenment Ltd. Device and Method for Measuring Physiological Parameters
JP2008253560A (en) * 2007-04-05 2008-10-23 Shinichi Yoshida Device for detecting pseudohypoglycemia and issuing alarm
CN102576375A (en) * 2009-05-29 2012-07-11 弗吉尼亚大学专利基金会 System coordinator and modular architecture for open-loop and closed-loop control of diabetes
CN103889317A (en) * 2011-06-23 2014-06-25 弗吉尼亚大学专利基金会 Unified platform for monitoring and control of blood glucose levels in diabetic patients
CN106137214A (en) * 2016-08-12 2016-11-23 上海移宇科技股份有限公司 A kind of transcutaneous analyte sensing equipment and installation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8152789B2 (en) * 2001-10-23 2012-04-10 Medtronic Minimed, Inc. System and method for providing closed loop infusion formulation delivery
US8423113B2 (en) * 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
EP2125078A1 (en) * 2007-03-27 2009-12-02 Koninklijke Philips Electronics N.V. Automatic drug administration with reduced power consumption
US7879026B2 (en) * 2007-09-07 2011-02-01 Asante Solutions, Inc. Controlled adjustment of medicine dispensation from an infusion pump device
US8257300B2 (en) * 2009-05-22 2012-09-04 Abbott Diabetes Care Inc. Safety features for integrated insulin delivery system
US10195343B2 (en) * 2010-02-05 2019-02-05 Deka Products Limited Partnership Devices, methods and systems for wireless control of medical devices
US20140012117A1 (en) * 2012-07-09 2014-01-09 Dexcom, Inc. Systems and methods for leveraging smartphone features in continuous glucose monitoring
US10357606B2 (en) * 2013-03-13 2019-07-23 Tandem Diabetes Care, Inc. System and method for integration of insulin pumps and continuous glucose monitoring
CN104622480B (en) * 2013-11-12 2017-12-05 上海移宇科技股份有限公司 Single needle integrated-type artificial pancreas
EP3174577A4 (en) * 2014-07-30 2018-04-18 Tandem Diabetes Care, Inc. Temporary suspension for closed-loop medicament therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070255122A1 (en) * 2004-08-30 2007-11-01 G.R. Enlightenment Ltd. Device and Method for Measuring Physiological Parameters
JP2008253560A (en) * 2007-04-05 2008-10-23 Shinichi Yoshida Device for detecting pseudohypoglycemia and issuing alarm
CN102576375A (en) * 2009-05-29 2012-07-11 弗吉尼亚大学专利基金会 System coordinator and modular architecture for open-loop and closed-loop control of diabetes
CN103889317A (en) * 2011-06-23 2014-06-25 弗吉尼亚大学专利基金会 Unified platform for monitoring and control of blood glucose levels in diabetic patients
CN106137214A (en) * 2016-08-12 2016-11-23 上海移宇科技股份有限公司 A kind of transcutaneous analyte sensing equipment and installation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3562395A4 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865299B2 (en) 2008-08-20 2024-01-09 Insulet Corporation Infusion pump systems and methods
US12064591B2 (en) 2013-07-19 2024-08-20 Insulet Corporation Infusion pump system and method
US11386996B2 (en) 2014-01-30 2022-07-12 Insulet Netherlands B.V. Therapeutic product delivery system and method of pairing
US11596740B2 (en) 2015-02-18 2023-03-07 Insulet Corporation Fluid delivery and infusion devices, and methods of use thereof
US11929158B2 (en) 2016-01-13 2024-03-12 Insulet Corporation User interface for diabetes management system
US12106837B2 (en) 2016-01-14 2024-10-01 Insulet Corporation Occlusion resolution in medication delivery devices, systems, and methods
US11857763B2 (en) 2016-01-14 2024-01-02 Insulet Corporation Adjusting insulin delivery rates
US11724027B2 (en) 2016-09-23 2023-08-15 Insulet Corporation Fluid delivery device with sensor
US12076160B2 (en) 2016-12-12 2024-09-03 Insulet Corporation Alarms and alerts for medication delivery devices and systems
US12042630B2 (en) 2017-01-13 2024-07-23 Insulet Corporation System and method for adjusting insulin delivery
US11969579B2 (en) 2017-01-13 2024-04-30 Insulet Corporation Insulin delivery methods, systems and devices
USD1020794S1 (en) 2018-04-02 2024-04-02 Bigfoot Biomedical, Inc. Medication delivery device with icons
US11565043B2 (en) 2018-05-04 2023-01-31 Insulet Corporation Safety constraints for a control algorithm based drug delivery system
US12090301B2 (en) 2018-05-04 2024-09-17 Insulet Corporation Safety constraints for a control algorithm based drug delivery system
AU2019347755B2 (en) * 2018-09-28 2023-02-02 Insulet Corporation Activity mode for artificial pancreas system
WO2020069406A1 (en) * 2018-09-28 2020-04-02 Insulet Corporation Activity mode for artificial pancreas system
JP2022501139A (en) * 2018-09-28 2022-01-06 インスレット コーポレイション Activity mode for artificial pancreas system
US11628251B2 (en) 2018-09-28 2023-04-18 Insulet Corporation Activity mode for artificial pancreas system
US11565039B2 (en) 2018-10-11 2023-01-31 Insulet Corporation Event detection for drug delivery system
USD1024090S1 (en) 2019-01-09 2024-04-23 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery
EP4149584A4 (en) * 2019-05-17 2024-06-05 Medtrum Technologies Inc. Bilaterally driven closed-loop artificial pancreas
EP4149586A4 (en) * 2019-05-17 2024-07-10 Medtrum Tech Inc Bilaterally driven closed-loop artificial pancreas
EP4151251A4 (en) * 2019-05-17 2024-07-10 Medtrum Tech Inc Double-sided-driving smart control infusion device, and closed-loop artificial pancreas
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
US11957875B2 (en) 2019-12-06 2024-04-16 Insulet Corporation Techniques and devices providing adaptivity and personalization in diabetes treatment
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
US12036389B2 (en) 2020-01-06 2024-07-16 Insulet Corporation Prediction of meal and/or exercise events based on persistent residuals
WO2022116539A1 (en) * 2020-01-21 2022-06-09 Medtrum Technologies Inc. Analyte detection system
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11986630B2 (en) 2020-02-12 2024-05-21 Insulet Corporation Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
US12121700B2 (en) 2020-07-22 2024-10-22 Insulet Corporation Open-loop insulin delivery basal parameters based on insulin delivery records
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US12115351B2 (en) 2020-09-30 2024-10-15 Insulet Corporation Secure wireless communications between a glucose monitor and other devices
US12128215B2 (en) 2020-09-30 2024-10-29 Insulet Corporation Drug delivery device with integrated optical-based glucose monitor
US12121701B2 (en) 2021-01-29 2024-10-22 Insulet Corporation Systems and methods for incorporating co-formulations of insulin in an automatic insulin delivery system
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
US11738144B2 (en) 2021-09-27 2023-08-29 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery
US12097355B2 (en) 2023-01-06 2024-09-24 Insulet Corporation Automatically or manually initiated meal bolus delivery with subsequent automatic safety constraint relaxation

Also Published As

Publication number Publication date
EP3562395A1 (en) 2019-11-06
EP3562395A4 (en) 2020-07-22
US20190307958A1 (en) 2019-10-10
US11534548B2 (en) 2022-12-27

Similar Documents

Publication Publication Date Title
US11534548B2 (en) System and method for a closed loop control in an artificial pancreas
CN108261585B (en) System and method for closed-loop control of artificial pancreas
EP1848323B1 (en) Bolus estimator for semi-closed loop infusion system
US11412994B2 (en) System and method for algorithm adjustment applying motions sensor in a CGM system
EP3077023B1 (en) Bolus dosing feedback for the management of diabetes
TW201837762A (en) Insulin-on-board accounting in an artificial pancreas system
US11551812B2 (en) Prediction based delivering or guiding of therapy for diabetes
US20230033130A1 (en) Closed-loop artificial pancreas controlled by body movements
US20210220559A1 (en) Minimally burdensome blood glucose management for insulin-requiring diabetes
CN108281200A (en) A kind of method of the adjustment algorithm in dynamic blood sugar monitoring system and the dynamic blood sugar monitoring system of application this method
US20220168506A1 (en) Systems and methods for optimizing medicament dosing
WO2022164738A1 (en) Automated insulin delivery system using pramlintide
US20180147348A1 (en) Audio bolus with improved safety for use in a drug delivery system
JP2016116948A (en) Liquid injection system
US20220181015A1 (en) Monitoring glucose level using different graphical representations
US20220133999A1 (en) Monitoring of physiological parameters with impedance measurement
Cohen Continuous glucose monitoring and pumps
WO2022125688A1 (en) Monitoring glucose level using different graphical representations
JP5971283B2 (en) Fluid injection system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16925387

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016925387

Country of ref document: EP

Effective date: 20190730